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Abstract
Background: Multiplex cytometric bead assay (CBA) have a number of advantages over ELISA for antibody testing,
but little information is available on standardization and validation of antibody CBA to multiple Plasmodium
falciparum antigens. The present study was set to determine optimal parameters for multiplex testing of antibodies
to P. falciparum antigens, and to compare results of multiplex CBA to ELISA.
Methods: Antibodies to ten recombinant P. falciparum antigens were measured by CBA and ELISA in samples from
30 individuals from a malaria endemic area of Kenya and compared to known positive and negative control plasma
samples. Optimal antigen amounts, monoplex vs multiplex testing, plasma dilution, optimal buffer, number of
beads required were assessed for CBA testing, and results from CBA vs. ELISA testing were compared.
Results: Optimal amounts for CBA antibody testing differed according to antigen. Results for monoplex CBA testing
correlated strongly with multiplex testing for all antigens (r = 0.88-0.99, P values from <0.0001 - 0.004), and
antibodies to variants of the same antigen were accurately distinguished within a multiplex reaction. Plasma
dilutions of 1:100 or 1:200 were optimal for all antigens for CBA testing. Plasma diluted in a buffer containing 0.05%
sodium azide, 0.5% polyvinylalcohol, and 0.8% polyvinylpyrrolidone had the lowest background activity. CBA
median fluorescence intensity (MFI) values with 1,000 antigen-conjugated beads/well did not differ significantly
from MFI with 5,000 beads/well. CBA and ELISA results correlated well for all antigens except apical membrane
antigen-1 (AMA-1). CBA testing produced a greater range of values in samples from malaria endemic areas and less
background reactivity for blank samples than ELISA.
Conclusion: With optimization, CBA may be the preferred method of testing for antibodies to P. falciparum antigens, as
CBA can test for antibodies to multiple recombinant antigens from a single plasma sample and produces a greater
range of values in positive samples and lower background readings for blank samples than ELISA.
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Background
Most studies that have determined antibody responses to
Plasmodium falciparum antigens and vaccine candidates in
human plasma samples have used enzyme linked immuno-
sorbent assay (ELISA) [1,2]. Recent advances in bead-based
flow cytometry have made multiplex cytometric bead assay
(CBA) antibody testing an attractive alternative to ELISA
testing. The Luminex100 system can simultaneously quanti-
tate up to 100 different proteins, peptides, DNA fragments
or RNA fragments from a 5 μl sample in one well of a
microtiter plate [3]. The multiplex assay is a bead format
assay in which each bead set is internally color-coded with
different ratio of red to infrared dyes, such that the Lumi-
nex100 can classify each bed set separately. The beads in
multiplex assay anchor the antigens, as opposed to ELISA
where the surfaces of the wells of microtiter plate anchor
the antigen. The Luminex100 has two lasers; one laser beam
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excites the internal colored dyes for classification of the
bead sets, while the other laser excites the reporter fluoro-
chrome phycoerythrin (PE) [4,5]. Through classification of
the bead set, various bead sets are distinguished, which cor-
respond to up to 100 different analytes that the machine
can quantitate, while the amount of analyte present in the
plasma, serum or supernatant is quantified by excitation of
the reporter fluorochrome [6].
Prior studies have reported use of the multiplex
assay for antibody determination to P. falciparum anti-
gens [7-11], and comparison studies of multiplex anti-
body measurements and traditional monoplex ELISA
have shown a high correlation [4,11,12]. However, these
studies have used a variety of different protocols and test
antigens. There are, to date, limited published studies
that provide information on assay optimization condi-
tions or comparisons of antigen and plasma concentra-
tions for multiplex testing. To provide standards for
testing that will allow wider use of this technique by
other researchers, optimal parameters for multiplex assay
were determined and compared with results of ELISA.
The assessed assay characteristics included: the optimal
malaria antigen amount for CBA, optimal plasma dilu-
tions for both CBA and ELISA assays, plasma buffer
choice for CBA, comparison of MFI between single vs.
multiplex CBA, optimization of the numbers of micro-
spheres per reaction for CBA, testing of CBA readout
with multiple variants of an antigen in a single test, and
comparison of optimized CBA with ELISA.
Methods
Plasma samples
For validation and standardization of the multiplex
assay of antibodies to P. falciparum antigens, a plasma
pool made of 30 plasma samples from adults living in
a Ugandan area of seasonal malaria transmission (positive
control pool samples) [13] and seven plasma samples from
North American individuals never exposed to malaria
(negative control samples) was used. For comparison of
antibody testing by CBA and ELISA to multiple P. falcip-
arum antigens, samples from 30 individuals from a malaria
endemic area of western Kenya were used [14]. Kenyan
samples were obtained from both children and adults, to
enable testing of a broad range of antibody values. Written
informed consent was obtained from the study participants
or, in the case of minors, from their parent or guardian.
Ethical approval for the study was obtained from Kenya
Medical Research Institute National Ethical Review Com-
mittee and the Institutional Review Boards of Makerere
University and University of Minnesota.
Plasmodium falciparum recombinant and peptide antigens
The ten recombinant P. falciparum antigens used for
testing were apical membrane antigen-1 (AMA-1, full
length ectodomain, 3D7 and FVO strains), erythrocyte-
binding antigen (EBA-175, non-glycosylated region II),
glutamate rich protein (GLURP, conserved non-repeat
N-terminal region, amino acids 25–514, R0; and repeat
C-terminal region, amino acids 705–1178, R2, 3D7
strain), merozoite surface protein-1 (MSP-119, E-KNG
variant; MSP-142, 3D7, FUP and FVO strains), and mer-
ozoite surface protein-3 (MSP-3, C-terminus, FVO
strain) were used for testing. Recombinant AMA-1 was
expressed in Escherichia coli and provided by David
Lanar, Walter Reed Army Institute for Research. Recom-
binant MSP-142 and MSP-3 were expressed in Escheri-
chia coli, and recombinant EBA-175 was expressed in
Pichia pastoris, and provided by David Narum, National
Institutes of Health. Recombinant GLURP was expressed
in Escherichia coli and provided by Michael Theisen,
Statens Seruminstitut, Copenhagen, Denmark. Recom-
binant MSP-119 expressed in Saccharomyces cerivisiae,
was provided by the Malaria Research and Reference Re-
agent Resource Center (Manassas, VA), and originally
deposited there by David Kaslow. Blank samples con-
sisted of the plasma diluent alone.
Coupling of recombinant antigens to microspheres for
the cytometric bead assay (CBA)
Microspheres were purchased from Luminex Corpor-
ation (Austin, TX). The bead stock was resuspended by
gentle inversion for 1 min. An aliquot of 612, 500 beads
was removed and centrifuged at 16, 000 g (Labnet Wood
bridge, NJ) for 3 min. After discarding the supernatant,
100 μl of distilled water was added and centrifuged at
16, 000 g for 3 min. Beads were resuspended in 80 μl of
activation buffer, 100 mM monobasic sodium phosphate
(Sigma, S3139); pH 6.2, by vortexing (Scientific Indus-
tries Bohemia, NY) and sonication, 20 sec each. To ac-
tivate the beads for cross-linking to proteins, 10 μl of
50 mg/mlN- hydroxysulfosuccinimide sodium salt (Sigma,
56485) was added to the beads and mixed by vortexing for
10 sec at moderate speed. Next, 10 μl of 50 mg/ml N-[3-
dimethylaminopropyl] – N`-ethylcarbodiimidehydrochlor-
ide (Sigma, E1769) was added and the beads mixed again
by vortexing for 10 sec at moderate speed. All incubations
of beads were performed in the dark (covered with foil).
The bead mixture was rotated on a rotary shaker (Labnet
Edison, NJ) at room temperature for 20 min and vor-
texed for 10 sec at 10 min and at 20 min, both at moder-
ate vortexing speed. Beads were pelleted by centrifuging
at 16, 000 g for 5 min and washed twice with 250 μl of
100 mM morpholineethane sulfonic acid (MES), (Sigma,
M2933), pH 6.0 buffer. Finally, beads were centrifuged at
16, 000 g for 5 min to pellet. To coat the beads with
antigens, pelleted beads were resuspended with the rele-
vant antigen and the volume adjusted to 500 μl per reac-
tion by addition of coupling buffer (100 mM MES pH
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6.0). Beads were conjugated to 0.5, 1, 2 and 5, 10 and 1,000
μg of different antigens. The antigen and activated beads
mixture was incubated on a rotary shaker for 2 h at room
temperature in the dark to allow bead coupling to occur.
After being coated with proteins beads were centrifuged at
16, 000 g for 3 min and washed twice with 250 μl of PBS-
TBN (PBS, 0.1% BSA, 0.02% Tween, 0.05% sodium azide)
and resuspended in 200 μl of PBS-TBN. To determine the
percentage recovery after the coupling procedure, coupled
beads were counted on a haemocytometer (Hausser Scien-
tific Horsham, PA).
Testing for IgG antibodies to P. falciparum antigens by CBA
The volume of working solution (50 μl/ well) was calcu-
lated together with the number of beads that would result
in 1,000 beads/region/well or 5,000 beads/region/well.
Bead stocks were then combined in a 15 ml amber conical
tube and diluted with PBNT (0.1% BSA, 0.05% Tween 20,
0.05% sodium azide in PBS) to result in 100 microspheres/
μl or 20 microspheres/μl. 96 well-millipore microtiter
plates (MABVN 1250, Millipore corporation, Billerica,
MA) were pre-wetted with 100 μl of PBNT/well and
aspirated using a millipore vacuum manifold and 50
μl of working bead solution was transferred to it.
Plasma samples were thawed at room temperature,
mixed and centrifuged at 16,000 g for 3 min. Plasma
was diluted through a series of concentrations: 1:100,
1:200, 1:400, 1:1000, 1:2000 and 1:4000. Plasma sam-
ples were diluted in either buffer A (1xPBS, 0.1%
BSA, 0.05% Tween 20, and 0.05% sodium azide) or
buffer B (1xPBS, 1% BSA, 0.05% Tween 20, 0.05% so-
dium azide, 0.5% polyvinylalcohol, and 0.8% polyvinyl-
pyrrolidone). Buffer A is the standard buffer used by
other studies of multiplex CBA for P. falciparum anti-
gens [9], while buffer B has been used for multiplex
antibody testing to other antigens and found to de-
crease background reactivity [15].
Fifty μl of diluted plasma was added to each of the
well of the microtiter plate. The plasma was mixed with
the beads three times by pipetting up and down. The
plates were incubated in the dark on a shaking micro-
plate shaker (IKAWMTS, Wilmington, NC) at 600 rpm
for 30 sec, followed by 300 rpm for 30 min. Plates were
aspirated using a millipore vacuum manifold and washed
twice with 100 μl/well of PBNT, and beads were resus-
pended in 50 μl PBNT by pipetting. 50 μl of diluted
1:1,000 goat antihuman IgG (gamma- chain specific, F
(ab`)2 fragment-R-phycoerythrin (Sigma, P-8047 St. Louis,
MO) in PBNT was added to each well, and incubated in
the dark with shaking at 600 rpm for 30 sec, followed by
300 rpm for 30 min. Plates were aspirated using a millipore
vacuum manifold and washed twice with 100 μl/well
PBNT. The beads were resuspended in 100 μl PBNT by
mixing and analysed on bioplex machine (Hercules, CA).
The reader was set to read a minimum of 100 beads with
of unique fluorescent signature/region and the results
expressed as median fluorescence intensity (MFI).
Testing for IgG antibodies to P. falciparum antigens by
ELISA
To validate the multiplex assay, similar plasma samples
were tested for IgG antibodies to the same P. falciparum
antigens by enzyme-linked immunosorbent assay (ELISA).
Recombinant antigens were dissolved in 0.01 M PBS to
concentrations: 0.1 μg/ml for (AMA-1 3D7, AMA-1 FVO,
EBA-175 and GLURP-R2), 0.2 μg/ml for (MSP-142 FVO,
MSP-142 3D7, and MSP-142 FUP), 0.5 μg/ml for (GLURP-
R0, MSP-119 and MSP-3 FVO). These antigen concentra-
tions were found to be optimal in previous studies for
AMA-1, EBA-175, MSP-142 [1], GLURP-R0 [16-19],
GLURP-R2 [16,18], MSP-119 [20] and MSP-3 [21]. Fifty
microlitres of antigen solution was added to Immulon-4
plates (Dynex Technologies,Chantilly, VA). Following over-
night incubation at 4°C, washing with PBS-0.05% Tween
20, and blocking in 5% (wt/vol) nonfat powdered milk in
PBS, duplicate 50 μl samples of serum diluted through a
series of concentrations ranging from 1:50, 1:100, 1:200,
1:500, 1:1000, and 1:2000 in 5% powdered milk were added
to wells and incubated for 2 h at room temperature.
After washing with PBS −0.05% Tween 20, 50 μl of al-
kaline phosphatase-conjugated goat anti-human IgG
(Jackson ImmunoResearch, West Grove, PA) diluted
1:1,000 in 5% powdered milk was added and incu-
bated for 1 h. After extensive washing with PBS-0.05%
Tween 20, p-nitrophenylphosphate was added in accord-
ance with the manufacturer’s instructions (Sigma, S0942
St. Louis, MO). The optical density (OD) was measured at
405 nm (Molecular Devices, Sunnyvale, CA).
Statistical analysis
The degree of association between MFI or OD values was
assessed using Pearson’s correlation (r). Comparison of
MFI values with Buffer A vs. Buffer B was done using Stu-
dent’s t-test. All statistical tests were 2-sided and a P value
of less than or equal to 0.05 was considered to be statisti-
cally significant for all comparisons. Analyses were con-
ducted with Stata software version 10.0 (Stata Corporation,
College Station, TX).
Results
Optimal amount of antigen for multiplex CBA
To determine optimal amounts of antigen for testing,
612,500 beads were coupled with differing amounts of anti-
gens (Table 1). For antigen amount testing, the coated
beads were incubated with plasma diluted to 1:200 from
the positive pool sample (a mixture of plasma from 30
adults from a malaria seasonal transmission area of
Uganda). Antigen amounts of 0.5, 1, 2, 5 and 10 μg of
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antigen were each used to coat duplicate wells, and a posi-
tive pool sample was placed in each well. The optimal anti-
gen amount was the amount that yielded the highest
average MFI value. The optimal amount for MSP- 142 FUP,
MSP- 142 3D7 and GLURP-R0 was 0.5 μg; for AMA-1
3D7, MSP-142 FVO,MSP-3 FVO was 1 μg; for AMA-1
FVO and EBA-175 was 2 μg; and for MSP-119 was 10 μg.
The optimal amount for GLURP-R2 was not tested separ-
ately, and the same amount as for GLURP-R0 (0.5 μg) was
used in multiplex testing.
Monoplex and multiplex CBA formats
To determine how multiplexing influences MFI values
in CBA assay, monoplex and multiplex assays were com-
pared using the full 10-plex of P. falciparum anti-
gens. Plasma IgG antibodies against each antigen
were tested in a monoplex format (10 antigens tested
separately) and as a 10-plex assay (in which anti-
bodies to all antigens were tested in a single reaction
well). For this experiment, eight plasma samples from
individuals from malaria endemic area were used,
and 5,000 beads/region/well were tested (Table 1).
Plasma samples were diluted 1:200 (Figure 1). Results
showed that MFI values for monoplex and multiplex
were similar and statistically significant correlations
between the two formats for all antigens was
observed, with a Pearson’s correlation coefficient (r)
ranging from 0.88 to 0.99, and all P values <0.0001
except for MSP-142 FUP, P = 0.004 and MSP-142 3D7,
P = 0.0003. Importantly, microspheres coupled to dif-
ferent allelic variants of the same antigen did not dif-
fer in monoplex vs multiplex testing, demonstrating
that there were no significant problems with cross-
reactivity in multiplex testing, even with multiple
variants of the same antigen included in testing.
Optimal plasma dilution for multiplex CBA and ELISA
assays
Optimal plasma dilution was determined by both multi-
plex CBA and ELISA for each antigen. Thirty samples
from individuals from a malaria endemic area of Kenya,
seven samples from North Americans never exposed to
malaria and positive pool plasma samples were used for
this testing (Table 1). Plasma was diluted to concentra-
tions of 1:100, 1:200, 1:400, 1:1000, 1:2000 and 1:4000
for CBA, and 1:100, 1:200, 1:500, 1:1000 and 1:2000 for
ELISA. Different concentration ranges were chosen be-
cause OD values of ELISA decreased more rapidly than
MFI values, such that values at 1:2000 were extremely
low and approached North American control values for
instance MSP-3 and MSP-119 (Figure 2). In contrast, the
MFI values of CBA at 1:2000 were still well above North
American control values. Multiplex CBA testing demon-
strated consistently low MFI values for samples from
North Americans never exposed to malaria, and these
values generally decreased as plasma dilution increased
(Figure 3). Plasma dilution of 1:100 provided the highest
OD on ELISA testing for all antigens while mean MFI
values were highest in malaria endemic samples diluted at
1:100 for all antigens. Nine samples showed a small in-
crease in MFI from a 1:100 to a 1:200 dilution for the
MSP-142 alleles, suggesting a minor prozone effect, but the
differences were smaller than the decreases seen with a de-
crease in dilution from 1:100 to 1:200 with all other
Table 1 Parameters tested in the CBA assay
Experimental condition
tested
Values tested Type and number of plasma samples used Outcome
Amount of antigen 0.5, 1, 2, 5 and 10 μg Positive pool (see Methods) in duplicate
wells per antigen amount
Different antigens had different
optimal amounts (see Results)
Plasma buffer component BSA, polyvinyl alcohol, polyvinylpyrrolidone
concentrations
North American (non-malaria exposed)
control pool and positive plasma pool
Buffer B had similar MFI values to
Buffer A for positive plasma pool
samples, but lower MFI values
than Buffer A for NA controls
BSA
Polyvinylalcohol Buffer A (0.1%, 0%, 0%) vs. Buffer B
(1%, 0.5%, 0.8%)
Polyvinylpyrrolidone
Plasma dilution 1:100, 1:200, 1:400, 1:1,000, 1:2,000 and
1:4,000
30 samples from persons from a malaria
endemic area, 7 North American control
samples and duplicate positive pool
plasma samples
Optimal 1:100 or 1:200
Assay format Monoplex (each Ag) 8 malaria endemic plasma samples Multiplex and monoplex gave
similar values
Multiplex (10 different Ags)
Number of microspheres
per reaction
5000 beads/analyte/well, 1000 beads/
analyte/well
3 North American, 16 malaria endemic
samples
1000 and 5000 beads/analyte/well
gave similar values




Parameters optimized in the multiplex cytometric bead based assay (CBA) assay with a set of variables investigated, description of samples used and standardized
values that gave optimal results.
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Figure 1 Correlation of data between monoplex and 10-plex CBA in testing plasma samples by antigen. Plasma from individuals in a
malaria endemic area, (n = 8).
Ondigo et al. Malaria Journal 2012, 11:427 Page 5 of 17
http://www.malariajournal.com/content/11/1/427
Figure 2 Effect of plasma dilution on IgG antibody ELISA OD values of plasma from persons in a malaria endemic area, (n = 30) and persons
never exposed to malaria, (n = 7).OD =optical density. OD values on Y-axis differ according to antigen.
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samples. An example was for MSP-142 FUP, for which anti-
body MFI values increased for five persons and decreased
for 25 persons from a malaria endemic area (Figure 4).
Samples from North American individuals never
exposed to malaria also showed an approximately nor-
mal distribution at all dilutions for 1:100, 1:200, 1:400
and 1:2000 dilutions for MSP-142 FUP (Figure 5). In
contrast, ELISA values for North American control sam-
ples showed much greater variability, did not decrease
with increasing plasma dilution (Figure 2), and were
often not normally distributed for 1:100, 1:200, 1:500
and 1:2000 dilutions (e.g., for MSP-142FUP, Figure 6).
MFI values of blank wells (beads in diluent buffer only)
in CBA testing were almost uniformly 0 or 1, making back-
ground reactivity a non-issue with CBA testing (Figure 7),
while blank wells in ELISA testing sometimes had low and
sometimes high OD readings (Figure 8), creating more
variability in assessment of the North American control
Figure 3 Effect of plasma dilution on IgG antibody CBA logarithm MFI values of plasma from persons in a malaria endemic area,
(n = 30) and persons never exposed to malaria, (n = 7). MFI = Median Fluorescence Intensity.
Figure 4 MFI values for antibodies to MSP-142 FUP in
individuals from a malaria endemic area, (n = 30) at 1:100 and
1:200 plasma dilutions.
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and malaria endemic sample OD values, if blank OD
values are subtracted from the control and malaria en-
demic sample values.
For CBA or ELISA testing in which there is no refer-
ence standard for antibody concentration, arbitrary units
(AU) are often used to define antibody levels. Arbitrary
units are used to standardize antibody values across
plates [22]. For antibodies to P. falciparum antigens, AU
is calculated using plasma samples from individuals (in
this study, North Americans) never exposed to malaria.
The mean OD or MFI of the North American plasma
samples plus three standard deviations of the OD or
MFI values is the cutoff value for 1 AU. The same North
American samples are tested on every plate. Every test
sample is then divided by the cutoff OD or MFI value to
come up with an AU value, and a sample is categorized
as “positive” by either multiplex or ELISA if the AU
value us greater than ≥1. For this study, 30 North
American control samples were tested, and seven sam-
ples chosen that are representative of the 30 samples,
providing the same mean and standard deviation, for
each plate, as testing all 30 samples on each plate would
almost double the number of plates required. It is par-
ticularly important with this method, which has been
used by others [22-26] that the samples provide a non-
skewed range of MFI or OD values. The increased range,
consistently normal distribution of North American con-
trol samples, and lower background values obtained with
CBA as compared to ELISA, made calculation of arbi-
trary units more accurate and reliable with CBA than
with ELISA.
For CBA, plasma dilutions of 1:100 or 1:200 generally
provided the best combination of AU range and sufficient
discrimination between North American control samples
and blank (diluent alone) wells. At dilutions greater than
1:400, MFI values became so low (e.g., mean (SD) values
for MSP-3 for 1:1000, 1:2000 and 1:5000 were 5.5 (1.4), 3.6
(0.9) and 1.4 (0.5), respectively) that although they were
higher than the blank well values of 0 or 1, they were con-
sidered too close to the blank well values to be useful in
calculating arbitrary units. Together, the findings lead to a
conclusion that a plasma dilution of 1:100 or 1:200 was op-
timal for most antigens in the CBA assay to allow deter-
mination of antibody level for the antigen in an individual.
Figure 5 Set of graphs across different dilutions overlaid with a normal density curve of CBA MFI valuesin plasma from persons never
exposed to malaria to MSP-142 FUP, (n = 7).
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Because of the few samples with increase MFI at 1:200 for
the MSP-142 antigens, a 1:200 dilution was chosen as the
standard dilution for CBA.
AU values as calculated from ELISA testing had a
much smaller range of minimum to maximum values
than corresponding values calculated from CBA testing.
For all antigens, a 1: 100 plasma dilution appeared to be
the optimal dilution for ELISA testing.
Reducing non specific background reactivity in CBA testing
To investigate reduction of non-specific background re-
activity, two buffers were compared with plasma pooled
from North American individuals (a mixture of seven
North American plasma samples) and positive pooled
samples. Pooled samples of each type were tested in
quadruplicate for each buffer at a dilution of 1:200.
Buffer A (1xPBS, 0.1% BSA, 0.05% Tween 20, and
0.05% sodium azide, pH 7.4) was compared to Buffer
B (1xPBS, 1% BSA, 0.05% Tween 20, 0.05% sodium
azide, 0.5% polyvinylalcohol, 0.8% polyvinylpyrrolidone,
pH 7.4; see Methods section for rationale). The two
buffers were compared using a six-plex CBA (AMA-1
3D7, AMA-1 FVO, EBA-175, MSP-142 3D7, MSP-142
FUP and MSP-142 FVO).
The two buffers yielded similar MFI values for the
positive pool samples for all, (Figure 9A), with statisti-
cally significant differences only for EBA-175 (buffer B >
buffer A) and MSP-142 FUP (buffer A > buffer B). In
contrast, MFI values for the non-malaria exposed North
American plasma pool were significantly lower for buffer
B for all six antigens (Figure 9B). The pooled positive
plasma samples also had reduced bead aggregation when
buffer B was used compared to buffer A. Buffer B thus
provided greater differentiation in MFI values between
plasma samples from malaria-exposed as compared to
non-exposed individuals.
Optimizing the number of beads per CBA analyte per well
Standard testing protocols for CBA recommend 5,000
beads per analyte per well [3,11,12,27-29], but using
large numbers of beads significantly increases expense.
The number of beads per region per well used for each
analyte throughout the optimization process was 5,000
as per microsphere manufacturer’s recommendations.
Figure 6 Set of graphs across different dilutions overlaid with a normal density curve of ELISA OD values in plasma from persons
never exposed to malaria to MSP-142 FUP, (n = 7).
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To determine if similar results could be obtained with a
lower number of beads, a comparison of MFI values
obtained with 5,000 beads/analyte/well and 1,000 beads/
analyte/well was performed. For this comparison pur-
poses, sixteen plasma samples from individuals from a
malaria endemic area of Kenya, three North American
control samples, and one positive pool sample, all
diluted to 1:200 were tested. MFI values were essentially
identical for all antigens tested with the two different
bead numbers (all r≥ 0.99, all P < 0.0001), (Figure 10). A
minimum of 100 beads/well was read by the bioplex ma-
chine for each analyte.
Reproducibility of the CBA coupling process
To evaluate the reproducibility of the coupling process,
coupling reactions were performed on two different days
(one week apart). Having established the optimal
amounts of antigen suitable for coupling, 612,500 beads
were coupled to respective optimal amounts to AMA- 1
3D7 and GLURP-R0 and 2-plex antibody detection was
performed using a positive plasma pool sample, two
North American control samples, and three samples
from individuals from malaria endemic Kenya, all diluted
1:200 Absolute MFI values generated between the two
coupling reactions were compared. The two coupling
reactions produced almost identical results (both r≥ 0.99,
P < 0.0001) (Figure 11).
Concordance between multiplex CBA and ELISA assay
OD values by ELISA and MFI values by CBA were
compared for samples from 20 individuals from malaria
endemic Kenya and North Americans. Correlations be-
tween CBA and ELISA were strong (r > 0.7) and highly
significant (P < 0.001) for all antigens except AMA-1,
(Figure 12).
Discussion
A number of recent papers have used multiplex CBA
testing to assess for the presence of antibodies to P. fal-
ciparum antigens [8,10]. In this study, a comprehensive
assessment of experimental parameters to optimize
multiplex cytometric bead assay (CBA) testing of anti-
bodies to P. falciparum antigens is provided. A recent
paper by Ambrosino et al. characterized optimization of
plasma dilution and amount of antigen for CBA malaria
antibody testing and focused on testing antibodies to
peptides of various P. falciparum antigens. This paper
adds to the findings of prior papers by assessing optimal
plasma dilution and antigen amount for several recom-
binant antigens not previously tested, investigating anti-
genic variants in the same multiplex testing, establishing
optimal diluent buffer for the lowest background re-
activity, and demonstrating that the testing can be per-
formed accurately with significantly less beads than
have previously been used in malaria studies. This
study also demonstrates the specific advantages CBA
Figure 7 MFI values at different dilutions of plasma from persons never exposed to malaria, (n = 7) and blank to EBA-175 (7A and 7B)
and GLURP-R2 (7C and 7D).
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may have over ELISA in antibody testing when there
is no absolute reference standard, and relative units
must be devised using samples from individuals with-
out exposure to the pathogen to compare measure-
ments of exposed populations.
Prior studies have documented similar results for CBA
and ELISA for measurement of antibodies to P. falciparum
or Plasmodium vivax antigens in malaria endemic popula-
tions [11,12]. Studies of antibodies to other infectious
organisms have similarly shown that CBA compares well
to established reference assays for these organisms [30-33].
Advantages noted over ELISA include specimen conserva-
tion, the ability to measure multiple analytes simultan-
eously, reduction in sample processing time due to kinetics
Figure 8 OD values at different dilutions of plasma from persons never exposed to malaria, (n = 7) and blank to EBA-175 (8A) and
GLURP-R2 (8B).
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of the assay, and cost minimization. The present study
adds to this literature by demonstrating optimization of
antigen concentration, plasma dilution, buffer solution,
and number of beads. The study demonstrates that anti-
bodies to antigenic variants can be tested in the same well
(multiplex) and results are virtually identical to results of
testing any variant alone by CBA (monoplex). It also pro-
vides evidence for the superiority of this testing as com-
pared to ELISA testing in terms of providing less
background, better differentiation of “positive” responses,
Figure 9 Comparison of CBA MFI values to P. falciparum antigens using Buffer A vs. Buffer B. plasma pool from persons in a malaria
endemic area (Figure 9A) and plasma pool from persons never exposed to malaria (Figure 9B).
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Figure 10 Correlation of data from CBA testing with 5,000 beads/analyte/well vs. 1,000 beads/analyte/well. Plasma from persons in a
malaria endemic area (n = 16), plasma from persons never exposed to malaria (n = 3) and a positive plasma pool.
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and a broader dynamic range of antibody level values. To-
gether, these findings support CBA as a precise, accurate
and efficient alternative to ELISA for testing antibodies to
multiple P. falciparum antigens, including multiple var-
iants of the same antigen.
Determining appropriate working amounts of anti-
gens is important in controlling surface density of the
malaria antigens on the bead surface. Coupling small
amounts may result in sub-optimal coating and low
activity (less antibody binding), while too much anti-
gen could result in precipitation and aggregation of
the beads on the bottom of the microtiter well surface
and this may impair the surface suspension antibody
binding. Additionally, one would like to use the low-
est amount of antigen that will provide the desired
binding of antigens [34]. Reduction of background ac-
tivity will enable malaria immunologists to accurately
measure low-level antibodies, particularly in travellers
[7,35,36] and in individuals under medication or indi-
viduals who are in recovery phase since antibodies
have been shown to decline after malaria episodes
[37,38].
Comparison between the 10-plex CBA and individ-
ual ELISA assays showed strong and highly signifi-
cant correlations for all antigens except AMA-1
(Figure 12). The reasons for this discrepancy with
AMA-1 are not clear. AMA-1 is among the most im-
munogenic P. falciparum antigens, and average MFI
values for both AMA-1 variants were much higher
than for other antigens, while OD values showed a
similar distribution to that seen for other antigens.
Low values were seen for both assays with North
American controls, so it is not clear which assay
more accurately reflected the range of AMA-1 anti-
body values in this population. This study documen-
ted an increase in MFI going from a plasma dilution
of 1:100 to 1:200 for a few individuals for the antigen
MSP-142 only. This suggested evidence of a modest
prozone phenomenon in these individuals. These
findings demonstrate that some degree of comprom-
ise is required in decisions on a final dilution, as one
dilution may not be the ideal for all antigens.
In the present study, long-term storage of multiplex
beads, to see how long they could be used was not
tested. Other studies have found that they provide
slightly reduced MFI values after 7 and 12 months
after initial bead coupling, if stored at 4°C [39,40]. Fu-
ture studies will be required to confirm the study find-
ings and assess longer storage periods of the coupled
beads. Lyophilization of coupled bead sets, as used in
a recent study [9], may provide an attractive alterna-
tive for long-term use of the same bead sets on differ-
ent samples over time.
Conclusion
The findings from the present study provide a basis
for improved multiplex CBA testing, as the study
testing provides information that will allow those
testing by CBA to reduce background reactivity,
optimize antigen concentration and plasma dilution,
and use a five-fold lower number of beads for test-
ing. Protocols will need to be individually tailored for
specific antigens, but the results here provide a clear
template for testing protocols that will allow for
rapid customization and comparison testing. The
present study also provides evidence of the increased
dynamic range of CBA testing as compared to ELISA
for this testing. The methods described in this study
should assist in standardizing multiplex CBA antibody
testing for multiple P. falciparum antigens, and allow it to
become an important tool in seroepidemiology studies
assessing population-based immunity in the face of chan-
ging transmission.
Figure 11 Regression plots of MFI data comparing 2-plex CBA
results for IgG antibodies to AMA-1 3D7 and GLURP-R0 from
plasma samples tested on separate days.
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Figure 12 Correlation of CBA MFI values and ELISA OD values for antibodies to P. falciparum antigens in individuals from a malaria
endemic area, (n = 20).
Ondigo et al. Malaria Journal 2012, 11:427 Page 15 of 17
http://www.malariajournal.com/content/11/1/427
Competing interest
The authors declare that no competing interests exist. The director of Kenya
Medical Research Institute approved this article for publication.
Authors’ contributions
BNO helped in the design aspects of the study, validated and performed
assays, literature search, data analysis, drafting of the manuscript and
transferring technology to field laboratory. SOG and BMH validated and
performed assays and data acquisition. GSP assisted in data acquisition,
helped in the design aspects of the study and intellectual content of the
manuscript. GAA, LAO and AVO provided intellectual input and revision of
the manuscript. CCJ conceived the idea and led the study design,
implementation of the program and drafting of the manuscript and editing
and review of the manuscript. All authors read and approved the final
manuscript.
Source of support
CCJ is supported by National Institutes of Health (U01 AI056270), and BNO is
supported by Fogarty International center (D43 TW0080085) and
Government of Kenya Ministry of Higher Education Science and Technology,
National Council of Science and Technology PhD competitive funds.
Acknowledgements
The authors thank Grace Meyer for assistance in performing ELISA and David
Narum, David Lanar, Michael Theissen and Malaria Research and Reference
Reagent Resource Center (MR-4) for provision of recombinant antigens used
in the testing. The authors are also grateful to the study participants and the
director KEMRI.
Author details
1Department of Biomedical Science and Technology, Maseno University,
Maseno, Kenya. 2Department of Pediatrics, University of Minnesota,
Minneapolis, MN, USA. 3Center for Global Health Research, Kenya Medical
Research Institute, Kisumu, Kenya.
Received: 5 July 2012 Accepted: 20 December 2012
Published: 21 December 2012
References
1. Noland GS, Hendel-Paterson B, Min XM, Moomann AM, Vulule JM, Narum
DL, Lanar DE, Kazura JW, John CC: Low prevalence of antibodies to pre-
erythrocytic but not blood-stage Plasmodium falciparum antigens in an
area of unstable malaria transmission compared to prevalence in an
area of stable malaria transmission. Infect Immun 2008, 76:5721–5728.
2. Olutu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, Lang T,
Gould J, Dubois MC, Jongert E, Vansadia P, Carter T, Njuguna P, Awuondo
KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B,
Villafana T, Lapierre D, Ballou WR, Cohen J, Lemnge MM, Peshu N, Marsh K,
Riley EM, von Seidlein L, Bejon P: Efficacy of RTS, S/AS01E malaria vaccine
and exploratory analysis on anti-circumsporozoite antibody titres and
protection in children aged 5–17 months in Kenya and Tanzania: a
randomised controlled trial. Lancet Infect Dis 2011, 11:102–109.
3. Lal G, Balmer P, Stanford E, Martin S, Warrington R, Borrow R: Development
and validation of a nonaplex assay for the simultaneous quantitation of
antibodies to nine Streptococcus pneumoniae serotypes. J Immunol
Methods 2005, 296:135–147.
4. Cham GK, Kurtis J, Lusingu J, Theander TG, Jensen AT, Turner L: A semi-
automated multiplex high-throughput assay for measuring IgG
antibodies against Plasmodium falciparum erythrocyte membrane
protein 1 (PfEMP1) domains in small volumes of plasma. Malar J 2008,
12:108.
5. Vignali DA: Multiplexed particle-based flow cytometric assays. J Immunol
Methods 2000, 243:243–255.
6. Giavedoni LD: Simultaneous detection of multiple cytokines and
chemokines from nonhuman primates using luminex technology.
J Immunol Methods 2005, 301:89–101.
7. Ambrosino E, Dumoulin C, Orlandi-Pradines E, Remoue F, Toure-Balde A, Tall
A, Sarr JB, Poinsignon A, Sokhna C, Puget K, Trape JF, Pascual A, Druilhe P,
Fusai T, Rogier C: A multiplex assay for the simultaneous detection of
antibodies against 15 Plasmodium falciparum and Anopheles gambiae
saliva antigens. Malar J 2010, 9:317.
8. Cham GK, Turner L, Kurtis JD, Mutabingwa T, Fried M, Jensen AT, Lavstsen T,
Hviid L, Duffy PE, Theander TG: Hierarchial, domain type-specific acquisition of
antibodies to Plasmodium falciparum erythrocyte membrane protein 1 in
Tanzania children. Infect Immun 2010, 78:4653–4659.
9. Cham GK, Turner L, Lusingu J, Vestergaard L, Mmbando BP, Kurtis JD,
Jensen AT, Salanti A, Lavstsen T, Theander TG: Sequential, ordered
acquisition of antibodies to Plasmodium falciparum erythrocyte
membrane 1 domains. J Immunol 2009, 183:3356–3363.
10. Chang SP, Kayatani AK, Terrientes ZI, Herrera S, Leke RG, Taylor DW: Shift in
epitope dominance of IgM and IgG responses to Plasmodium falciparum
MSP1 block 4. Malar J 2010, 9:14.
11. Fouda GG, Leke RF, Long C, Druilhe P, Zhou A, Taylor DW, Johnson AH:
Multiplex assay for simultaneous measurement of antibodies to multiple
Plasmodium falciparum antigens. Clin Vaccine Immunol 2006, 13:1307–1313.
12. Fernandez-Becerra C, Sanz S, Brucet M, Stanisic DI, Alves FP, Camargo EP,
Alonso PL, Mueller I, de Portillo HA: Naturally- acquired humoral immune
responses against the N- and C- termini of the Plasmodium vivax MSP1
protein in endemic regions of Brazil and Papua New Guinea using a
multiplex assay. Malar J 2010, 9:29.
13. Idro R, Bitarakwate E, Tumwesigire S, John CC: Clinical manifestations of
severe malaria in the highlands of southwestern Uganda. Am J Trop Med
Hyg 2005, 72:561–567.
14. John CC, Moormann AM, Pregibon DC, Sumba PO, McHugh MM, Narum DL,
Lanar DE, Schluchter MD, Kazura JW: Correlation of high levels of
antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens
and protection from infection. Am J Trop Med Hyg 2005, 73:222–228.
15. Waterboer T, Sehr P, Pawlita M: Suppression of non-specific binding in
serological Luminex assays. J Immunol Methods 2006, 309:200–204.
16. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S,
Nkrumah FK, Theander TG, Hviid L: Naturally acquired antibodies to the
glutamate-rich protein are associated with protection against
Plasmodium falciparum malaria. J Infect Dis 2000, 181:1202–1205.
17. Lusingu J, Vestergaard LS, Alifrangis M, Mmbando BP, Theisen M, Kitua AY,
Lemnge MM, Theander TG: Cytophilic antibodies to Plasmodium
falciparum glutamate rich protein are associated with malaria protection
in an area of holoendemic transmission. Malar J 2005, 4:48.
18. Nébié I, Cuzin-Ouattara N, Diallo DA, Cousens SN, Theisen M, Corradin G,
Traoré AS, Esposito F: Humoral responses to defined malaria antigens in
children living since birth under insecticide treated curtains in Burkina
Faso. Acta Trop 2003, 88:17–25.
19. Theisen M, Dodoo D, Toure-Balde A, Soe S, Corradin G, Koram KK, Kurtzhals
JA, Hviid L, Theander TG, Akanmori B, Ndiaye M, Druilhe P: Selection of
glutamate-rich protein long synthetic peptides for vaccine development:
antigenicity and relationship with clinical protection and
immunogenicity. Infect Immun 2001, 69:5223–5229.
20. Diallo TO, Remoue F, Gaayeb L, Schacht AM, Charrier N, De Clerck D,
Dompnier JP, Pillet S, Garraud O, N'Diaye AA, Riveau G: Schistosomiasias
coinfection in children influences acquired immune response against
Plasmodium falciparum malaria antigens. PLoS One 2010, 5:e12764.
21. Segeja MD, Mmbando BP, Seth MD, Lusingu JP, Lemnge MM: Acquisition
of antibodies to merozoite surface protein 3 among residents of
Korogwe, north eastern Tanzania. BMC Infect Dis 2010, 10:55.
22. Fidock DA, Gras-Masse H, Lepers JP, Brahimi K, Benmohamed L, Mellouk S,
Guerin-Marchand C, Londono A, Raharimalala L, Meis JF: Plasmodium
falciparum liver stage antigen-1 is well conserved and contains potent B
and T cell determinants. J Immunol 1994, 153:190–204.
23. Ceravolo IP, Sanchez BA, Sousa TN, Guerra BM, Soares IS, Braga EM,
McHenry AM, Adams JH, Brito CF, Carvalho LH: Naturally acquired
inhibitory antibodies to Plasmodium vivax Duffy binding protein are
short-lived and allele-specific following a single malaria infection. Clin
Exp Immunol 2009, 156:502–510.
24. Dent AE, Chelimo K, Sumba PO, Spring MD, Crabb BS, Moomann AM, Tisch
DJ, Kazura JW: Temporal stability of naturally acquired immunity to
Merozoite Surface Protein- 1 in Kenyan adults. Malar J 2009, 8:162.
25. Richards JS, Stanisic DI, Fowkes FJ, Tavul L, Dabod E, Thompson JK, Kumar S,
Chitnis CE, Narum DL, Michon P, Siba PM, Cowan AF, Mueller I, Beeson JG:
Association between naturally antibodies to erythrocyte-binding
antigens of Plasmodium falciparum and protection from malaria and
high-density parasitemia. Clin Infect Dis 2010, 51:e50–e60.
26. Storti-Melo LM, Souza-Neiras WC, Cassiano GC, Taveira LC, Cordeiro AJ,
Couto VS, Póvoa MM, Cunha MG, Echeverry DM, Rossit AR, Arévalo-Herrera
Ondigo et al. Malaria Journal 2012, 11:427 Page 16 of 17
http://www.malariajournal.com/content/11/1/427
M, Herrera S, Machado RL: Evaluation of the naturally acquired antibody
immune response to the Pv200L N-terminal fragment of Plasmodium
vivax merozoite surface protein-1 in four areas of the Amazon Region of
Brazil. Am J Trop Med Hyg 2011, 84:58–63.
27. Bay JT, Garred P: Rapid bead-based immunoassay for measurement of
mannose-binding lectin. Scand J Immunol 2009, 69:570–575.
28. de Vore NC, Huynh S, Dobrovolskaia EN, Slater JE: Multiplex microbead
measurements for the characterization of cat and ragweed allergen
extracts. Ann Allergy Asthma Immunol 2010, 105:351–358.
29. Sun M, Manolopoulou J, Spyroglou A, Beuschlein F, Hantel C, Wu Z,
Bielohuby M, Hoeflich A, Liu C, Bidlingmaier M: A microsphere-based
duplex competitive immunoassay for the simultaneous measurements
of aldosterone and testosterone in small sample volumes: validation in
human and mouse plasma. Steroids 2010, 75:1089–1096.
30. Reder S, Riffelmann M, Becker C, Wirsing von Konig CH: Measuring
immunoglobulin G antibodies to tetanus toxin, diphtheria toxin, and
pertusis toxin with single- antigen enzyme- linked immunosorbent
assays and a bead-based multiplex assay. Clin Vaccine Immunol 2008,
15:744–749.
31. Shoma S, Verkaik NJ, de Vogel CP, Hermans PW, van Selm S, Mitchell TJ, van
Roosmalen M, Hossain S, Rahman M, Endtz HP, van Wamel WJ, van Belkum
A: Development of a multiplexed bead-based immunoassay for the
simultaneous detection of antibodies to 17 pneumococcal proteins. Eur J
Clin Microbiol Infect Dis 2011, 30:521–526.
32. van der Heyde HC, Burns JM, Weidanz WP, Horn J, Gramaglia I, Nolan JP:
Analysis of antigen-specific antibodies and their isotypes in
experimental malaria. Cytometry A 2007, 71:242–250.
33. Wagner B, Freer H, Rollins A, Erb HN: A fluorescent bead-based multiplex
assay for the simulaneous detection of antibodies to B. burgdorferi outer
surface proteins in canine serum. Vet Immunol Immunopathol 2011,
140:190–198.
34. TechNote 204: Adsorption to microspheres. Bang Laboratories, Inc; 2008.
35. Jelinek T, Blüml A, Löscher T, Nothdurft HD: Assessing the incidence of
infection with Plasmodium falciparum among international travelers. Am
J Trop Med Hyg 1998, 59:35–37.
36. Zamarrón Fuertes P, Pérez-Ayala A, Pérez Molina JA, Norman FF, Monge-
Maíllo B, Navarro M, López-Vélez R: Clinical and epidemiological
characteristics of imported infectious diseases in Spanish travelers. J
Travel Med 2010, 17:303–309.
37. Achtman AH, Bull PC, Stephens R, Langhorne J: Longevity of the immune
response and memory to blood- stage malaria infection. Curr Top
Microbiol Immunol 2005, 297:71–102.
38. Kinyanjui SM, Conway DJ, Lanar DE, Marsh K: IgG antibody responses to
Plasmodium falciparum merozoite antigens in Kenyan children have a
short half-life. Malar J 2007, 6:82.
39. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE,
Molina DM, Burk CR, Waisberg M, Jasinkas A, Tan X, Doumbo S, Doumtabe
D, Kone Y, Narum DL, Liang X, Doumbo OK, Miller LH, Doolan DL, Baldi P,
Felgner PL, Pierce SK: A prospective analysis of the Ab response to
Plasmodium falciparum before and after a malaria season by protein
microarray. Proc Natl Acad Sci U S A 2010, 107:6958–6963.
40. Cham GK, Kurtis J, Lusingu J, Theander TG, Jensen AT, Turner L: A semi-
automated multiplex high-throughput assay for measuring IgG
antibodies against Plasmodium falciparum erythrocyte membrane
protein 1 (PfEMP1) domains in small volumes of plasma. Malar J 2008,
7:108.
doi:10.1186/1475-2875-11-427
Cite this article as: Ondigo et al.: Standardization and validation of a
cytometric bead assay to assess antibodies to multiple Plasmodium
falciparum recombinant antigens. Malaria Journal 2012 11:427.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ondigo et al. Malaria Journal 2012, 11:427 Page 17 of 17
http://www.malariajournal.com/content/11/1/427
